Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Current Leases (2019 - 2025)

Historic Current Leases for Corcept Therapeutics (CORT) over the last 7 years, with Q3 2025 value amounting to $1.0 million.

  • Corcept Therapeutics' Current Leases rose 14305.56% to $1.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 14305.56%. This contributed to the annual value of $829000.0 for FY2024, which is 44900.66% up from last year.
  • As of Q3 2025, Corcept Therapeutics' Current Leases stood at $1.0 million, which was up 14305.56% from $1.0 million recorded in Q2 2025.
  • Over the past 5 years, Corcept Therapeutics' Current Leases peaked at $2.3 million during Q1 2022, and registered a low of $44000.0 during Q2 2024.
  • Moreover, its 5-year median value for Current Leases was $984000.0 (2025), whereas its average is $960842.1.
  • As far as peak fluctuations go, Corcept Therapeutics' Current Leases tumbled by 8688.16% in 2023, and later soared by 221136.36% in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Current Leases stood at $526000.0 in 2021, then soared by 117.3% to $1.1 million in 2022, then plummeted by 86.79% to $151000.0 in 2023, then surged by 449.01% to $829000.0 in 2024, then grew by 26.66% to $1.0 million in 2025.
  • Its Current Leases stands at $1.0 million for Q3 2025, versus $1.0 million for Q2 2025 and $984000.0 for Q1 2025.